Last reviewed · How we verify
Budesonide-Surfactant
Budesonide is a corticosteroid that reduces airway inflammation, while the surfactant component improves drug delivery and reduces surface tension in the lungs.
Budesonide is a corticosteroid that reduces airway inflammation, while the surfactant component improves drug delivery and reduces surface tension in the lungs. Used for Asthma (maintenance and reliever therapy), Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Budesonide-Surfactant |
|---|---|
| Sponsor | China Medical University Hospital |
| Drug class | Inhaled corticosteroid with surfactant excipient |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Budesonide works by binding to glucocorticoid receptors in airway epithelial cells, suppressing inflammatory cytokine production and reducing eosinophil infiltration. The surfactant component enhances pulmonary bioavailability and distribution of budesonide throughout the respiratory tract, improving therapeutic efficacy in treating airway inflammation.
Approved indications
- Asthma (maintenance and reliever therapy)
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Oral candidiasis
- Hoarseness
- Tremor
- Headache
- Throat irritation
Key clinical trials
- Little Lungs Study (PHASE1, PHASE2)
- The Budesonide in Babies (BiB) Trial (PHASE3)
- Steroids and Surfactant in Extremely Low Gestation Age Infants Dose Escalation Trial (PHASE1, PHASE2)
- Assessment Of Dose-Dependent Immunomodulatory Effect Of Alveofact With or Without Steroisd In Neonatal RDS (PHASE1)
- Intratracheal Budesonide/Surfactant Prevents BPD (PHASE4)
- Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease (PHASE4)
- Budesonia + Intratracheal Surfactant in Incidence of Bronchopulmonary Dysplasia (NA)
- Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Budesonide-Surfactant CI brief — competitive landscape report
- Budesonide-Surfactant updates RSS · CI watch RSS
- China Medical University Hospital portfolio CI